Armata Pharmaceuticals Inc
ARMP
Get informed when a big investor buys or sells
+ FollowMarket Cap$166.67M
Close$
$-10.87
332.3% downside
Current Fair Value
332.3% downsideOvervalued by 332.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $166.67 Million |
|---|---|
| Enterprise Value | $535.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.8 |
| Beta | 1.27 |
| Outstanding Shares | 36,530,284 |
Return
| Return on Equity | 90.70% |
|---|---|
| Return on Assets | -404.89% |
| Return on Invested Capital | -61.21% |
Valuation & Multiples
| P/E Ratio | -0.58 |
|---|---|
| PEG | -0.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.52 |
| Enterprise Value to Revenue | 132.47 |
| Enterprise Value to EBIT | -14.44 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.7 |
| Debt to Equity | -1.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$740,000
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$400,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.75%▲ 7.31% |
|---|---|
| Total Invested | $40.22M▲ 412.23% |
| Investors Holding | 45▲ 9.00% |
ESG Score
No data
About Armata Pharmaceuticals Inc
CEO: Todd Patrick